Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study

Clinical Rheumatology

Volumn 35, Issue 5, 2016, Pages 1281-1286

  Emmi, Giacomo ^a   Talarico, Rosaria ^b   Lopalco, Giuseppe ^c   Cimaz, Rolando ^d   Cantini, Fabrizio ^e   Viapiana, Ombretta ^f   Olivieri, Ignazio ^g   Goldoni, Matteo ^h   Vitale, Antonio ⁱ   Silvestri, Elena ^a   Prisco, Domenico ^a   Lapadula, Giovanni ^c   Galeazzi, Mauro ⁱ   Iannone, Florenzo ^c   Cantarini, Luca ⁱ  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e Hospital of Prato   (Italy)

^f UNIVERSITY OF VERONA   (Italy)

^g SAN CARLO HOSPITAL   (Italy)

^h UNIVERSITY OF PARMA   (Italy)

ⁱ UNIVERSITY OF SIENA   (Italy)

Author keywords

Anakinra; Anti interleukin 1; Beh et s disease; Biologics; Canakinumab; Therapy

Indexed keywords

CANAKINUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SKIN MANIFESTATION; TREATMENT RESPONSE; BEHCET SYNDROME; CLINICAL TRIAL; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84936882695     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-3004-0     Document Type: Article

References (22)

1. International Study Group for Behcet disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080
2. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 11:687–698
3. Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C et al (2015) Behçet’s syndrome patients exhibit specific microbiome signature. Autoimmun Rev 14:269–276
4. Gül A (2005) Behçet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 4:81–83
5. Tasliyurt T, Yigit S, Rustemoglu A, Gul U, Ates O (2013) Common MEFV gene mutations in Turkish patients with Behcet’s disease. Gene 530:100–103
6. Amoura Z, Dodé C, Hue S, Caillat-Zucman S, Bahram S, Delpech M et al (2005) Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet’s disease. Arthritis Rheum 52:608–611
7. Zou J, Guan JL (2014) Interleukin-1-related genes polymorphisms in Turkish patients with Behçet disease: a meta-analysis. Mod Rheumatol 24:321–326
8. Alexoudi I, Kapsimali V, Vaiopoulos A, Kanakis M, Vaiopoulos G (2011) Evaluation of current therapeutic strategies in Behçet’s disease. Clin Rheumatol 30:157–163
9. Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V et al (2014) Biological treatments in Behçet’s disease: beyond anti-TNF therapy. Mediators Inflamm 2014:107421
10. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA (2008) Resistant Behçet disease responsive to anakinra. Ann Intern Med 149:284–286
11. Emmi G, Silvestri E, Cameli AM, Bacherini D, Vannozzi L, Squatrito D et al (2013) Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol 31(3 Suppl 77):152–153
12. Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R et al (2013) Anakinra treatment in drug-resistant Behçet’s disease: a case series. Clin Rheumatol [Epub ahead of print]
13. Caso F, Rigante D, Vitale A, Lucherini OM, Cantarini L (2014) Efficacy of anakinra in refractory Behçet’s disease sacroiliitis. Clin Exp Rheumatol 32:S171
14. Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis 71:1589–1591
15. Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R (2012) Successful use of canakinumab in a patient with resistant Behçet’s disease. Clin Exp Rheumatol 30:S115
16. Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L et al (2014) Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet’s disease: a case series. Dermatology 228:211–214
17. Emmi G, Silvestri E, Ciucciarelli L, Squatrito D, Emmi L (2014) Reply: anti-IL1 blocking agents in drug-resistant Behçet’s syndrome: our little case series. Clin Exp Rheumatol 32(4 Suppl 84):S172
18. Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A et al (2012) Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 71:563–566
19. Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G et al (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet’s disease. Autoimmun Rev 14:1–9
20. Cantini F, Niccoli L, Goletti D (2014) Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 91:47–55
21. Botsios C (2005) Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev 4:162–170
22. Pagnini I, Bondi T, Simonini G, Giani T, Marino A, Cimaz R (2015) Successful treatment with canakinumab of a paediatric patient with resistant Behcet’s disease. Rheumatology. doi:10.1093/rheumatology/kev197